These strategies are supported by studies in hepatocellular carcinoma (HCC), where dual immunotherapy (anti-PD-L1/CTLA-4) with molecular agents improved antitumor response in patients with otherwise limited options (160, 161). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.